Core A Administrative Core The Administrative Core is under the Direction of the Program Director, Dr. Richard J. Whitiey. As the responsible Principal Investigator for the Program Project Grant, he will provide the scientiflc and administrative leadership for the overall program. He will be assisted in these tasks by Drs. G. Yancey Gillespie and James M. Markert, Program Co-Directors. Together, these Administrative Core Leaders will provide centralized management support, and collaborative research support for all research projects of this two-institution Program Project Grant. The purpose of this Core is to provide the administrative framework to facilitate the rapid and expeditious translation of our basic science advances into therapeutic opportunities for humans. The interdigitation of molecular virology, cellular biology. In vitro screening, animal model studies, and other facilitating work will be coordinated by the Administrative Core. Administrative funcflons also include oversight of operations and budgetary issues for all Program Project investigators and Core Leaders. Quarterly meetings with all of the Project and Core leaders will be organized and coordinated to ensure that the research activities proceed in a timely fashion and that all program participants have an informal forum to shape and focus the direction of the research activities. These meetings will also enhance the integration of project and core activities with each other, based on priorities that are identifled from results presented at each meeting. The Administrative Core will coordinate an annual meeting with the External Advisory Committee which will evaluate the progress of the individual Program projects and the services provided by the Cores. The External Advisory Committee is compised of 3 outstanding scientists. Dr. Thomas Shenk, virologist, Dr. Darell D. Bigner, glioma expert and Dr. Robert Martuza, a leader in viral oncolysis and clinical studies. All efforts will be focused on the flmely translation of the flndings on molecular biology of herpes simplex viruses and the cellular biology of the virus-host relation to the treatment of human malignant gliomas. This program project grant has the full support of the University of Alabama at Birmingham and the University of Chicago. Letters of support appear from Drs. C Garrison (President, UAB), E Capiluto (Provost, UAB), R Rich (Dean, School of Medicine, UAB), E Partridge (Director, UAB Comprehensvive Cancer Center), S Stagno (Chair, Department of Pediatircs) and M. LeBeau (Director, The University of Chicago Cancer Center).

Public Health Relevance

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
United States
Zip Code
Friedman, G K; Nan, L; Haas, M C et al. (2015) ??34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia. Gene Ther 22:348-55
Jackson, J D; McMorris, A M; Roth, J C et al. (2014) Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Ther 21:984-90
Cody, James J; Markert, James M; Hurst, Douglas R (2014) Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. PLoS One 9:e92919
Roth, Justin C; Cassady, Kevin A; Cody, James J et al. (2014) Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev 25:16-27
Widau, Ryan C; Parekh, Akash D; Ranck, Mark C et al. (2014) RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A 111:E484-91
Smith, Tyrel T; Roth, Justin C; Friedman, Gregory K et al. (2014) Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virother 2014:21-33
Markert, James M; Razdan, Shantanu N; Kuo, Hui-Chien et al. (2014) A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 22:1048-55
Pressey, Joseph G; Haas, Marilyn C; Pressey, Christine S et al. (2013) CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer 60:45-52
Liauw, Stanley L; Connell, Philip P; Weichselbaum, Ralph R (2013) New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med 5:173sr2
Gillory, Lauren A; Megison, Michael L; Stewart, Jerry E et al. (2013) Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. PLoS One 8:e77753

Showing the most recent 10 out of 150 publications